Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373:726-36. DOI: 10.1056/NEJMoa1502309

Vemurafenib in Multiple Nonmelanoma BRAF^{V600}-Mutated Cancers

Hyman DH, Puzanov I, Vivek Subbiah V et al.

Supplemental Materials

TABLE OF CONTENTS	PAGE
List of investigators	2
Figure S1. Study design.	3
Figure S2. Representative pretreatment and on-treatment response assessments.	4
Figure S3. Maximum percentage change from baseline in target lesion diameter sum.	5
Figure S4. Time to events by patient and best overall response (confirmed).	8
Table S1. International Melanoma Working Group Uniform Response Criteria	12
Table S2. Disease-Specific Patient Characteristics.	14
Table S3. Preliminary Efficacy by Cohort	18
Table S4. Common Adverse Events in All Patients Who Received Vemurafenib, Pooled Across Cohorts.	19
Table S5. Most Common Adverse Events by Cohort.	20
Reference	23

Study Investigators

France: Jean-Yves Blay, Mario Campone, Radj Gervais, Anthony Goncalves, Antoine Hollebecque, Nicolas
Isambert, Antoine Italiano, Florence Joly Lobbedez, Jean-Charles Soria
Germany: Ralf-Dieter Hofheinz, Martin Schuler, Jürgen Wolf
Spain: Andres Cervantes, Maria Elena Elez-Fernandez, Jesus Garcia-Foncillas Lopez, Manuel Hidalgo Medina,
Miguel Martin Jimenez, Josep Tabernero
United Kingdom: Ian Chau, Marianne Nicolson
United States: Omar Abdel-Wahab, Gregory Ayers, Jose Baselga, Donald Brooks, Emily Chan, Eli L. Diamond,
Alexander Drilon, Jason Faris, Janku Filip, John Gerecitano, Mrinal Gounder, James Harding, Thomas C. Havell,
III, Leora Horn, David Hyman, Razelle Kurzrock, Thomas Leonard-Martin, Craig Lockhart, Funda Meric-Bernstam,
Igor Puzanov, Noopur S. Raje, Gregory Riely, David Solit, Jeffrey Sosman, Vivek Subbiah, Apostolia Tsimberidou,
Anna Varghese, Martin Voss, Maria Weir

Figure S1. Study design. CT, indicates computed tomography; MRI, magnetic resonance imaging; RR, response

rate.

Screening period	Treatment period	Follow-up period
 BRAF^{v600} mutation assay analysis Tumor assessments with CT/MRI Medical history Physical examination 	 Primary end point: RR at Week 8 Secondary end points: efficacy, safety, and tolerability Study visits on Day 1, 15, and 29 and every 28 days thereafter 	any reason 28 days (± 5 any reason 28 days (± 5
Day –28 Da	y 1 Time on Study E	☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐

Figure S2. Pretreatment and on-treatment response assessments. (A) Non-small cell lung cancer. (B) Cholangiocarcinoma. (C) Anaplastic thyroid cancer. (D) Ovarian Cancer. (E) Pancreatic cancer. (F) Erdheim-Chester disease. (G) Langerhans cell histiocytosis. (H) Glioblastoma. (I) Salivary Gland Cancer.







Figure S3. Maximum percentage change from baseline in target lesion diameter sum. (A) NSCLC cohort.a,b (B) Colorectal cancer cohort (vemurafenib monotherapy).b (C) Colorectal cancer cohort (vemurafenib + cetuximab combination therapy). *Indicates patients in the dose escalation stage (dose levels 1 and 2).b (D) Cholangiocarcinoma cohort.b (E) ECD/LCH cohort. †Indicates patient has LCH.b (F) Anaplastic thyroid cancer cohort.b (G) Other tumor cohort.a,b,c aOne patient died before evaluation. bIncludes only patients who had measurable disease at baseline based on RECIST and at least one posttreatment tumor evaluation. cIncludes brain tumor, head and neck cancer, pancreatic cancer, esophageal and gastric cancer, sarcoma, low-grade serous ovarian cancer, multiple myeloma, and carcinoma of unknown primary. ECD/LCH indicates Erdheim-Chester disease/Langerhans cell histiocytosis; NSCLC, non-small cell lung cancer; PXA, pleomorphic xanthoastrocytoma; RECIST, Response Evaluation Criteria In Solid Tumors, version 1.1.







B. Colorectal cancer (vemurafenib monotherapy)






C. Colorectal cancer (vemurafenib + cetuximab)





F. Anaplastic thyroid



G. Other






Figure S4. Time to events by patient and best overall response (confirmed). (A) NSCLC cohort.a,b (B) Colorectal cancer cohort (vemurafenib monotherapy).b (C) Colorectal cancer cohort (vemurafenib + cetuximab). *Indicates patients in the dose escalation stage (dose levels 1 and 2).b (D) Cholangiocarcinoma cohort.b (E) ECD/LCH cohort. †Indicates patient has LCH.b (F) Anaplastic thyroid cancer cohort.b (G) Other tumors cohort.b,c Bar length for those patients who do not have disease progression (box) or death (circle) represents progression-free survival duration. BRAFV600G and unknown BRAFV600 mutations are indicated by V600G and V600Unk, respectively. aOne patient died before evaluation. bIncludes only patients who had measurable disease at baseline based on RECIST and at least one posttreatment tumor evaluation. cIncludes breast cancer (BC), cervical cancer (CC), brain tumors, head and neck cancer, esophageal and gastric cancer (ECG), pancreatic cancer, sarcoma, low-grade serous ovarian cancer, multiple myeloma, and carcinoma of unknown primary. AE indicates anaplastic ependymoma; CLC, cholangiocarcinoma; ECD/LCH, Erdheim-Chester disease/Langerhans cell histiocytosis; HNC, head and neck cancer; NSCLC, non-small cell lung cancer; OC, low-grade serous ovarian cancer; PXA, anaplastic pleomorphic xanthoastrocytoma; SGC, salivary gland carcinoma; TCC, thoracic clear cell.




A. NSCLC


B. Colorectal cancer (vemurafenib monotherapy)




C. Colorectal cancer (vemurafenib + cetuximab)




D. Cholangiocarcinoma








F. Anaplastic thyroid



G. Other



Legend

- VEM ongoing
- Time to Progression
- ♦ Time to Response
- Died

Table S1. International Melanoma Working Group Uniform Response Criteria (adapted with permission from

Macmillan Publishers Ltd, copyright 2006)¹

Response subcategory	Response criteria (each of the following criteria must be met) ^a
Complete response	Negative immunofixation on the serum and urine
	• Disappearance of any soft tissue plasmacytomas
	• \leq 5% plasma cells in bone marrow
Stringent complete response	All of the criteria of a complete response plus
	Normal free light chain ratio
	• Absence of clonal cells in bone marrow (repeat biopsy not needed) by
	immunohistochemistry or immunofluorescence ^b
Very good partial response	• Serum and urine M-protein detectable by immunofixation but not on
	electrophoresis or ≥90% or greater reduction in serum M-protein plus urine M-
	protein level <100mg per 24 h
Partial response	● ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein
	by \geq 90% or to <200mg per 24 h ^c
	• In addition to the above listed criteria, if present at baseline, a \geq 50% reduction
	in the size of soft tissue plasmacytomas is also required
Stable disease (not	• Not meeting criteria for complete response, very good partial response, partial
recommended for use as	response, or progressive disease
indicator of response)	
Response subcategory	Response criteria (one or more of the following criteria must be met) Learning (\$>250' for a baseling in
Progressive disease	Increase of $\ge 25\%$ from baseline in
	• Serum M-component (the absolute increase must be $\ge 0.5 \text{ g/dl})^d$
	 Urine M-component (the absolute increase must be ≥200 mg/24 h) Only in patients without measurable serum and urine M-protein levels:
	The absolute increase must be $>10 \text{ mg/dl}$ for the difference between
	involved and uninvolved free light chain levels
	• Bone marrow plasma cell percentage: the absolute % must be $\geq 10\%^{e}$
	 Definite development of new bone lesions or soft tissue plasmacytomas or
	definite increase in the size of existing bone lesions or soft tissue
	plasmacytomas
	• Development of hypercalcemia (corrected serum calcium >11.5 mg/dl or 2.65
	mmol/l) that can be attributed solely to the plasma cell proliferative disorder
Clinical relapse	• Direct indicators of increasing disease and/or end organ dysfunction (CRAB
-	features) ^d
	1. Development of new soft tissue plasmacytomas or bone lesions
	2. Definite increase in the size of existing plasmacytomas or bone lesions. A
	definite increase is defined as a 50% (and at least 1 cm) increase as
	measured serially by the sum of the products of the cross-diameters of the
	measurable lesion
	3. Hypercalcemia (>11.5 mg/dl) [2.65 mmol/l]
	4. Decrease in hemoglobin of $\geq 2 \text{ g/dl} [1.25 \text{ mmol/l}]$ 5. Disc in commensation by $\geq 2 \text{ mg/dl} [>177 \text{ umgl/l}]$
Dalance from complete	5. Rise in serum creatinine by $\geq 2 \text{ mg/dl} [\geq 177 \mu \text{mol/l}]$
Relapse from complete response (to be used only if	Reappearance of serum or urine M-protein by immunofixation or
endpoint is disease-free	electrophoresis $P_{\rm avalar}$ and $P_{\rm avalar}$ being the hone merrow.
survival)	 Development of ≥5% plasma cells in the bone marrow^e Appearance of any other sign of progression (i.e., new plasma store lution)
541 + 1 + 41 /	• Appearance of any other sign of progression (i.e., new plasmacytoma, lytic bone lasion or hyperselectric see below)
^a A 11 man and a sate series magning	bone lesion, or hypercalcemia see below)

^aAll response categories require two consecutive assessments made at anytime before the institution of any new therapy; all categories also require no known evidence of progressive or new bone lesions if radiographic studies were performed. Radiographic studies are not required to satisfy these response requirements.

^bPresence/absence of clonal cells is based upon the k/λ ratio.

^cIf the serum and urine M-protein are unmeasurable, $a \ge 50\%$ decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, $\ge 50\%$ reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was $\ge 30\%$.

^dFor progressive disease, serum M-component increases of ≥ 1 gm/dl are sufficient to define relapse if starting M-component is ≥ 5 g/dl.

^eRelapse from CR has the 5% cutoff versus 10% for other categories of relapse

Characteristic — no. (%)	All Enrolled Patients
NSCLC cohort	(n = 20)
Race	· · · · · ·
White	12 (60)
Black	1 (5)
Asian	0
Other	0
Not collected (per local regulations)	7 (35)
Smoking history	
Current smoker/former smoker	13 (65)
Never smoker	7 (35)
$BRAF^{V600}$ detection method*, n (%)	
Sanger	6 (30)
PCR	4 (20)
Sequenom	3 (15)
SNaPshot	4 (20)
NGS	3 (15)
Sites of metastasis	5 (15)
Liver	8 (40)
Lymph nodes	18 (90)
Pleura	11 (55)
Peritoneum	1 (5)
Skin	0
Skii	2 (10)
Bone	8 (40)
Brain	3 (15)
Other	7 (35)
	19 (95)
Any systemic therapy	19 (93)
Platinum-containing therapy* Docetaxel/paclitaxel*	10 (50)
*	(n = 10)
Colorectal cancer cohort (vemurafenib monotherapy)	(n = 10)
Primary tumor location	
Colon	6 (60)
Rectum	2 (20)
Colon and rectum	2 (20)
$BRAF^{V600}$ detection method*, n (%)	2 (20)
cobas 4800	2 (20)
Sanger	2 (20)
PCR	2 (20)
Sequenom	4 (40)
Sites of metastasis	
Liver	3 (30)
Lung	7 (70)
Lymph nodes	5 (50)
Pleura	1 (10)
Peritoneum	6 (60)
Soft tissues	1 (10)
Bone	2 (20)
Brain	1 (10)
Other	3 (30)
Any systemic therapy	10 (100)
FOLFOX*†	10 (100)

Table S2. Disease-Specific Patient Characteristics.

Characteristic — no. (%)	All Enrolled Patients
FOLFIRI*‡	8 (80)
Cetuximab or panitumumab (EGFR antibody)*	7 (70)
Bevacizumab*	5 (50)
Colorectal cancer cohort (vemurafenib/cetuximab)	(n = 27)
Primary tumor location	
Colon	22 (81)
Rectum	4 (15)
Colon and rectum	1 (4)
$BRAF^{V600}$ detection method*, n (%)	
cobas 4800	2 (7)
Sanger	3 (11)
PCR	9 (33)
Sequenom	5 (19)
SNaPshot	5 (19)
NGS	2 (7)
Other**	
Sites of metastasis	1 (4)
Liver	19 ((7))
	18 (67)
Lung	11 (41)
Lymph nodes	12 (44)
Pleura	2 (7)
Peritoneum	9 (33)
Skin	2 (7)
Soft tissues	1 (4)
Bone	1 (4)
Brain	0
Other	2 (7)
Any systemic therapy	27 (100)
FOLFOX*†	21 (78)
FOLFIRI*‡	21 (78)
Cetuximab or panitumumab (EGFR antibody)*	12 (44)
Bevacizumab*	20 (74)
Multiple myeloma cohort (included in "other" cohort for	(n = 5)
efficacy analysis)	
M protein	
Immunoglobulin M	5 (100)
International staging system at diagnosis	
Ι	2 (40)
II	2 (40)
III	1 (20)
IV	0
$BRAF^{V600}$ detection method*, n (%)	
Sequenom	1 (20)
Other**	4 (80)
Any systemic therapy	5 (100)
Thalidomide/lenalidomide*	5 (100)
Bortezomib/carfilzomib*	3 (60)
Etoposide*	3 (60)
Platinum-containing therapy*	3 (60)
Cholangiocarcinoma/biliary tract cancer cohort	(n = 8)
Origin of primary tumor	(n = 0)
Intrahepatic	6 (75)
mancpauc	0(73)

Characteristic — no. (%)	All Enrolled Patients
Perihilar	0
Distal	1 (13)
Other	1 (13)
Histology	
Adenocarcinoma	8 (100)
Other	0
$BRAF^{V600}$ detection method*, n (%)	
Sanger	2 (25)
PCR	2 (25)
Sequenom	1 (13)
NGS	3 (38)
Any systemic therapy	8 (100)
Platinum-containing therapy*	8 (100)
ECD/LCH cohort	(n = 18)
Histology	(11 10)
ECD	14 (78)
LCH	3 (17)
Langerhans cell sarcoma	1 (6)
$BRAF^{V600}$ detection method*, n (%)	1 (0)
cobas 4800	1 (6)
PCR	7 (39)
Sequenom	5 (28)
NGS	2 (11)
Other**	3 (17)
Sites of disease	5 (17)
Bone	14 (78)
Brain	7 (39)
Orbit	6 (33)
Soft tissues	6 (33)
Heart	5 (28)
Skin	5 (28)
Lung	4 (22)
Peritoneum	3 (17)
Retroperitoneal	3 (17)
Lymph nodes	2 (11)
Vessels	2 (11)
Pleura	1 (6)
Other	2 (11)
Any systemic therapy	11 (61)
Interferon*	4 (22)
Anakinra*	1 (6)
Anaplastic thyroid cancer cohort	(n = 7)
$BRAF^{V600}$ detection method*, n (%)	$(\Pi - I)$
Sanger	1 (14)
PCR	1 (14)
Sequenom	4 (57)
NGS	1 (14)
Sites of metastasis	1 (14)
Liver	0
Lung	5 (71)
Lung Lymph nodes	6 (86)
Pleura	1 (14)
ritula	1 (14)

Characteristic — no. (%)	All Enrolled Patients
Peritoneum	0
Skin	1 (14)
Soft tissues	0
Bone	2 (29)
Brain	0
Other	0
Any systemic therapy	7 (100)
Tyrosine kinase inhibitor therapy§*	4 (57)
Anthracycline-containing therapy*	3 (43)
Other tumors cohort*	(n = 27)
Brain	13 (50)
Glioma/glioblastoma/astrocytoma — no.	8
Pleomorphic xanthoastrocytoma — no.	4
Anaplastic ependymoma — no.	1
Head and neck	3 (12)
Carcinoma of unknown primary	3 (12)
Pancreas	2 (8)
Sarcoma	2 (8)
Ovary (low-grade serous)	1 (4)
Esophagus	1 (4)
Cervix	1 (4)
Breast	1 (4)
$BRAF^{V600}$ detection method*, n (%)	
Sanger	7 (26)
PCR	5 (19)
Sequenom	5 (19)
SNaPshot	4 (15)
NGS	3 (11)
Other**	3 (11)

ATC indicates anaplastic thyroid cancer; CRC, colorectal cancer; ECD/LCH, Erdheim-Chester disease/Langerhans cell histiocytosis; NSCLC, non-small cell lung cancer.

*Based on manual review of cohort listings.

**Includes capillary electrophoresis single-strand conformation analysis, single-strand conformation analysis, melting, locked nucleic acid, and pyrosequencing.

NGS denotes next-generation sequencing (includes FoundationOne, TAQMAN, and other non–Sanger-based high-throughput sequencing methods); PCR, polymerase chain reaction.

†Includes leucovorin, 5-flourouracil, and oxaliplatin.

‡Includes leucovorin, 5-flourouracil, and irinotecan.

§Includes pazopanib.

Table S3. Preliminary Efficacy by Cohort.

	NSCLC (n = 20)	CRC (n = 10)	CRC (n = 27)	CLC (n = 8)	ECD/LCH (n = 18)	ATC (n = 7)
Drug administered	Vemurafenib	Vemurafenib	Vemurafenib + cetuximab	Vemurafenib	Vemurafenib	Vemurafenib
Stage 1 — no.	7	7	7*	7	7	7
Stage 1 week 8 overall	14 (0.4-58)	0	0*	0	14 (0.4-58)	29 (4-71)
response rate — %						
(95% CI)						
CR — no. (%)	0	0	0*	0	1 (14)	0
PR — no. (%)	1 (14)	0	0*	0	0	2 (29)
SD — no. (%)	5 (71)	5 (71)	2 (29)*	4 (57)	6 (86)	0
PD — no. (%)	1 (14)	2 (29)	4 (57)*	3 (43)	0	4 (57)
Nonevaluable/missing — no. (%)	0	0	1 (14)*	0	0	1 (14)
Patients with at least	19 [‡]	10	26	8	14	7
one postbaseline						
assessment — no.						
Best overall response						
CR — no. (%)†	0	0	0	0	1 (7)	1 (14)
PR — no. (%)†	8 (42)	0	1 (4)	1 (13)	5 (36)	1 (14)
SD — no. (%)†	8 (42)	5 (50)	18 (69)	4 (50)	8 (57)	0
PD — no. (%)†	2 (11)	5 (50)	7 (27)	3 (38)	0	4 (57)
Missing — no. $(\%)^{\ddagger\ddagger}$	1 (5)	0	0	0	0	1 (14)
Response (CR+PR) —	8 (42)	0	1 (4)	1 (13)	6 (43)	2 (29)
no. % [95% CI]	[20 to 67]			[0.3 to 53]	[18 to 71]	[4 to 71]
Clinical benefit rate —	16 (84)	5 (50)	19 (73)	5 (63)	14 (100)	2 (29)
no. (%)†§ [95% CI]	[60 to 97]	[19 to 81]	[52 to 88]	[25 to 92]	[77 to 100]	[4 to 71]
Median PFS — days	223.0	138.0 (31.0,	113.0 (54.0,	Not	Not	Not
(95% CI)	(106.0, 330.0)	168.0)	155.0)**	determined	determined	determined
Events— no.	14	10	13	5	1	5
Median OS —days	NE	283.0	218.0	Not	Not	Not
(95% CI)		(172.0, NE)	(135.0, NE)**	determined	determined	determined
Events-no.	5	5	6	2	0	4

ATC, anaplastic thyroid cancer; CLC, cholangiocarcinoma; CRC, colorectal cancer; CR, complete response; ECD/LCH, Erdheim-Chester disease/Langerhans cell histiocytosis; NE, nonestimable; NSCLC, non-small cell lung cancer; PD, progressive disease; PR, partial response, SD, stable disease.

*Stage 1 was based on patients receiving dose level 3 in accordance with protocol.

†Denominator is number of patients with postbaseline assessment or early withdrawal.

‡All patients with missing data were early withdrawals.

§Clinical benefit rate is the sum of partial response, complete response, and stable disease.

**Median progression-free survival and median overall survival were calculated using the patients enrolled in dose level 3 (n = 21).

Adverse Event — no. (%)	Vemurafenib Monotherapy (n = 95)		
	All grades	Grade 3 or 4	
Any adverse event	93 (98)	69 (73)	
Most common adverse events ⁺	All grades	Grade 3 or 4	
Arthralgia	38 (40)	4 (4)	
Decreased appetite	28 (30)	2 (2)	
Nausea	27 (28)	1 (1)	
Hyperkeratosis	25 (26)	2 (2)	
Diarrhea	23 (24)	0	
Pruritus	23 (24)	0	
Skin papilloma	23 (24)	1 (1)	
Vomiting	23 (24)	1(1)	
Alopecia	21 (22)	0	
Asthenia	19 (20)	4 (4)	
Palmar-plantar erythrodysesthesia syndrome	19 (20)	1 (1)	
Select adverse events [‡]	All grades	Grade 3 [‡]	
Rash§	65 (68)	15 (16)	
Fatigue	53 (56)	11 (12)	
Photosensitivity reaction**	25 (26)	0	
Cutaneous squamous cell carcinoma ^{††}	22 (23)	22 (23)	
Noncutaneous squamous cell carcinoma ^{‡‡}	2 (2)	2 (2)	
Adverse event — no. (%)	Vemurafenib + cetu	iximab, All dose levels	
		= 27)	
	All grades	Grade 3 or 4	
Any adverse event	27 (100)	20 (74)	
Most common adverse events ⁺	All grades	Grade 3 or 4	
Diarrhea	12 (44)	1 (4)	
Arthralgia	12 (44)	1 (4)	
Abdominal pain	11 (41)	2 (7)	
Asthenia	8 (30)	0	
Decreased appetite	8 (30)	0	
Vomiting	7 (26)	0	
Nausea	7 (26)	0	
Erythema	7 (26)	0	
Lipase increased	6 (22)	6 (22)	
Select adverse events	All grades	Grade 3 [‡]	
Rash§	20 (74)	1 (4)	
Fatigue	14 (52)	0	
Photosensitivity reaction**	9 (33)	0	
Cutaneous squamous cell carcinoma ^{††}	3 (11)	3 (11)	
Noncutaneous squamous cell carcinoma ^{‡‡}	1 (4)	1 (4)	

Table S4. Common Adverse Events in All Patients Who Received Vemurafenib, Pooled Across Cohorts.*

*Cohort-specific adverse events are reported in Table S3.

[†]The most common adverse events were those that occurred in at least 20% of the patients.

‡No grade 4 or 5 selected adverse events were reported.

§Includes rash, rash maculopapular, erythema, folliculitis, rash papular, rash macular, rash pruritic, rash erythematous, and rash follicular.

Includes fatigue, asthenia, and cachexia.

**Includes photosensitivity reaction and sunburn.

††Includes squamous cell carcinoma of the skin and keratoacanthoma.

##Includes squamous cell carcinoma and squamous cell carcinoma of the tongue.

Adverse Event — no. (%)	All	Grade 3 or 4
NSCLC cohort (n = 20)		
Any adverse event	19 (95)	16 (80)
Most common adverse events*		
Decreased appetite	7 (35)	2 (10)
Nausea	7 (35)	0
Dyspnea	6 (30)	3 (15)
Hyperkeratosis	6 (30)	0
Vomiting	6 (30)	1 (5)
Hypertension	5 (25)	3 (15)
Pruritus	5 (25)	0
Pyrexia	5 (25)	0
Arthralgia	4 (20)	0
Alopecia	4 (20)	0
Constipation	4 (20)	0
Cough	4 (20)	0
Diarrhea	4 (20)	0
Dysgeusia	4 (20)	0
Neuropathy peripheral	4 (20)	0
Weight decreased	4 (20)	0
Selected adverse events	All grades	Grade 3 [†]
Rash‡	13 (65)	1 (5)
Fatigue§	12 (60)	4 (20)
Photosensitivity reaction	5 (25)	0
Cutaneous squamous cell carcinoma**	7 (35)	7 (35)
Noncutaneous squamous cell carcinoma ^{††}	0	0
CRC vemurafenib monotherapy cohort (n = 10)		
Any adverse event	10 (100)	5 (50)
Most common adverse events*		
Decreased appetite	6 (60)	0
Arthralgia	6 (60)	1 (10)
Hyperkeratosis	4 (40)	0
Pruritus	4 (40)	0
Dysgeusia	3 (30)	0
Milia	3 (30)	0
Mucosal inflammation	3 (30)	1 (10)
Skin papilloma	3 (30)	0
Alopecia	2 (20)	0
Dermal cyst	2 (20)	0
Erythema	2 (20)	0
Myalgia	2 (20)	0
Nausea	2 (20)	0
Papilloma viral infection	2 (20)	0
Peripheral sensory neuropathy	2 (20)	0
Weight decreased	2 (20)	0
Select adverse events	All grades	Grade 3^{\dagger}
Rash‡	7 (70)	3 (30)
Fatigue§	8 (80)	0
Photosensitivity reaction	1 (10)	0
Cutaneous squamous cell carcinoma**	1 (10)	1 (10)
Noncutaneous squamous cell carcinoma ^{‡‡}	0	0
Multiple myeloma cohort $(n = 5)$		
Any adverse event	5 (100)	5 (100)

 Table S5. Most Common Adverse Events* by Cohort.

Adverse Event — no. (%)	All	Grade 3 or 4
Most common adverse events in ≥ 2 patients		
Keratosis pilaris	2 (40)	1 (20)
Lower respiratory tract infection	2 (40)	1 (20)
Blood creatinine increased	2 (40)	0
Diarrhea	2 (40)	0
Hypokalemia	2 (40)	0
Seborrheic keratosis	2 (40)	0
Anemia	2 (40)	2 (40)
Select adverse events	All grades	Grade 3 [†]
Rash‡	3 (60)	0
Fatigue§	0	0
Photosensitivity reaction¶	2 (40)	0
Cutaneous squamous cell carcinoma**	0	0
Noncutaneous squamous cell carcinoma ^{††}	0	0
Cholangiocarcinoma cohort (n = 8)	0	0
Any adverse event	8 (100)	7 (88)
Most common adverse events*	0 (100)	/ (00)
Diarrhea	4 (50)	0
Nausea	4 (50)	0
		0
Arthralgia	3 (38)	
Decreased appetite	3 (38)	0
Vomiting	3 (38)	0
Alopecia	2 (25)	0
Back pain	2 (25)	1 (13)
Blood creatinine increased	2 (25)	0
Cholestasis	2 (25)	2 (25)
Cough	2 (25)	0
Dry skin	2 (25)	0
Dyspepsia	2 (25)	0
Dyspnea	2 (25)	1 (13)
Headache	2 (25)	0
Hyperbilirubinemia	2 (25)	0
Hyperglycemia	2 (25)	0
Hypokalemia	2 (25)	0
Hyponatremia	2 (25)	1 (13)
Lymphocyte count decreased	2 (25)	2 (25)
Select adverse events	All grades	Grade 3 [†]
Rash‡	7 (88)	1 (13)
Fatigue§	5 (63)	2 (25)
Photosensitivity reaction	1 (13)	0
Cutaneous squamous cell carcinoma**	1 (13)	1 (13)
Noncutaneous squamous cell carcinoma ^{††}	0	0
ECD/LCH cohort $(n = 18)$		
Any adverse event	18 (100)	17 (94)
Most common adverse events*		\\
Arthralgia	11 (61)	3 (17)
Skin papilloma	9 (50)	1 (6)
Hypertension	8 (44)	3 (17)
Pruritus	8 (44)	0
Alopecia	7 (39)	0
Palmar-plantar erythrodysesthesia syndrome	7 (39)	0
Diarrhea	6 (33)	0

Adverse Event — no. (%)	All	Grade 3 or 4
Dry skin	6 (33)	0
Hyperkeratosis	6 (33)	1 (6)
Nausea	6 (33)	0
Vomiting	6 (33)	0
Cough	5 (28)	0
Actinic keratosis	4 (22)	2 (11)
Blood creatinine increased	4 (22)	0
Lipase increased	4 (22)	1 (6)
Selected adverse events	All grades	Grade 3 [†]
Rash‡	14 (78)	5 (28)
Fatigue§	11 (61)	1 (6)
Photosensitivity reaction	5 (28)	0
Cutaneous squamous cell carcinoma**	8 (44)	8 (44)
Noncutaneous squamous cell carcinoma ^{††}	0	0
ATC cohort $(n = 7)$		
Any adverse event	6 (86)	3 (43)
Most common adverse events*		
Decreased appetite	3 (43)	0
Dysphagia	3 (43)	0
Pyrexia	3 (43)	1 (14)
Arthralgia	2 (29)	0
Candida infection	2 (29)	0
Chills	2 (29)	0
Cognitive disorder	2 (29)	0
Cough	2 (29)	0
Dehydration	2 (29)	1 (14)
Palmar-plantar erythrodysesthesia	2 (29)	0
syndrome		
Pruritus	2 (29)	0
Vomiting	2 (29)	0
Select adverse events	All grades	Grade 3^{\dagger}
Rash‡	4 (57)	1 (14)
Fatigue§	3 (43)	2 (29)
Photosensitivity reaction	2 (29)	0
Cutaneous squamous cell carcinoma**	1 (14)	1 (14)
Noncutaneous squamous cell carcinoma ^{††}	0	0

*The most common adverse events were those of any grade that occurred in at least 20% of the patients enrolled in the specific cohort.

[†]No grade 4 or 5 selected adverse events were reported.

‡Includes rash, rash maculopapular, erythema, folliculitis, rash papular, rash macular, rash pruritic, rash erythematous, and rash follicular.

§Includes fatigue, asthenia, and cachexia.

¶Includes photosensitivity reaction and sunburn.

**Includes squamous cell carcinoma of the skin and keratoacanthoma.

††Includes noncutaneous squamous cell carcinoma and squamous cell carcinoma of the tongue.

Reference

 Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.